Pharmaceutical

AstraZeneca and Alteogen agree on ALT-B4 platform tech

AstraZeneca has entered an exclusive licence agreement with Alteogen involving the latter’s ALT-B4 platform technology.

Mar 19, 2025 - 06:00
AstraZeneca and Alteogen agree on ALT-B4 platform tech
AstraZeneca has entered an exclusive licence agreement with Alteogen involving the latter’s ALT-B4 platform technology.
Read the original article

Tags:

Previous Article

Big tech meets biotech: Recursion and the AI gold rush in pharma 

Next Article

Investigating key strategies for optimising clinical trial supply chains in 2025

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: STAT+: A California court is setting a dangerous precedent over drug development (or lack thereof) liability

Opinion: STAT+: A California court is setting a dangero...

Feb 13, 2024

Ikena fires 35% of staff to funnel funds into clinical oncology programmes

Ikena fires 35% of staff to funnel funds into clinical ...

Jan 19, 2024

STAT+: Here’s why there aren’t many cheap, generic versions of pricey inhalers

STAT+: Here’s why there aren’t many cheap, generic vers...

Mar 19, 2023